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Liver failure is the major cause of death following liver resection. Post-resection portal ve-
nous pressure (PVP) predicts liver failure, is implicated in its pathogenesis, and when PVP is
reduced, rates of liver dysfunction decrease. The aim of the present study was to character-
ize the hemodynamic, biochemical, and histological changes induced by 80% hepatectomy
in non-cirrhotic pigs and determine if terlipressin or direct portacaval shunting can modu-
late these effects. Pigs were randomized (n=8/group) to undergo 80% hepatectomy alone
(control); terlipressin (2 mg bolus + 0.5–1 mg/h) + 80% hepatectomy; or portacaval shunt
(PCS) + 80% hepatectomy, and were maintained under terminal anesthesia for 8 h. The
primary outcome was changed in PVP. Secondary outcomes included portal venous flow
(PVF), hepatic arterial flow (HAF), and biochemical and histological markers of liver injury.
Hepatectomy increased PVP (9.3 +− 0.4 mmHg pre-hepatectomy compared with 13.0 +−
0.8 mmHg post-hepatectomy, P<0.0001) and PVF/g liver (1.2 +− 0.2 compared with 6.0 +−
0.6 ml/min/g, P<0.0001) and decreased HAF (70.8 +− 5.0 compared with 41.8 +− 5.7 ml/min,
P=0.002). Terlipressin and PCS reduced PVP (terlipressin= 10.4+− 0.8 mmHg, P=0.046 and
PCS = 8.3 +− 1.2 mmHg, P=0.025) and PVF (control = 869.0 +− 36.1 ml/min compared with
terlipressin = 565.6 +− 25.7 ml/min, P<0.0001 and PCS = 488.4 +− 106.4 ml/min, P=0.002)
compared with control. Treatment with terlipressin increased HAF (73.2 +− 11.3 ml/min) com-
pared with control (40.3 +− 6.3 ml/min, P=0.026). The results of the present study suggest
that terlipressin and PCS may have a role in the prevention and treatment of post-resection
liver failure.
Introduction
Post-resection liver failure (PLF) is a devastating complication that is resource intensive [1], carries con-
siderable morbidity, and remains the primary cause of death following major liver resection [2]. Up to
90% of patients undergoing major (>50%) hepatectomy experience some degree of liver dysfunction [3].
This becomes clinically significant in half and progresses to PLF in up to 10% [2].
Risk factors identified for the development of PLF include extent of resection, presence of underlying
parenchymal disease [2], elevated post-resection portal venous pressure (PVP) in non-cirrhotic patients
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[4], and pre-resection portal hypertension in cirrhotic patients [5]. Allard et al. [4] demonstrated that the risk of PLF
and dying increased when post-resection PVP in non-cirrhotic patients increased above a threshold of 21–22mmHg.
The risk of PLF was negligible when PVP remained at normal levels (≤10 mmHg).
In porcine models of major liver resection, where post-resection PVP is modulated by portacaval shunting [6],
mesocaval shunting [7,8], or by implantation of an adjustable vascular ring [9], the degree of post-resection liver
dysfunction is reduced. Performing portacaval or mesocaval shunting in patients undergoing major liver resection
adds complexity to the procedure; may increase morbidity through encephalopathy [10,11], could inhibit liver re-
generation due to the diversion of hepatotropic factors [12] and requires an additional procedure to close the shunt
once regeneration is complete. It is, therefore, desirable to explore strategies that reduce PVP without introducing
additional morbidity peri/post-resection.
Tri-glycyl-lysine-vasopressin (terlipressin) is metabolized in the circulation to lysine-vasopressin, where its effects
include reductions in PVP and portal venous flow (PVF) [13]. Terlipressin is widely used to treat complications
of portal hypertension in patients with cirrhosis. It reduces rebleeding following acute variceal hemorrhage [14,15];
improves renal recovery in hepatorenal syndrome [16–20]; and reduces PVF following split graft liver transplantation
[21]. Recent studies have also explored its effects after hepatectomy in rodents. Terlipressin reduced PVP following
90% hepatectomy [22], but had no effect on liver regeneration after 70% hepatectomy in rats [23]. Inmice, terlipressin
reduced PVP and increased liver regeneration after partial hepatectomy [24]. The effects of terlipressin on PVP after
major hepatectomy in the absence of cirrhosis in a large animal model have not been reported.
The current study set out to characterize the hemodynamic, biochemical, and histological changes induced by 80%
hepatectomy in non-cirrhotic pigs in a terminal anesthetic model and to determine if terlipressin or direct portacaval
shunting (PCS) could reverse these effects. We hypothesized that terlipressin and PCS would reduce PVP and PVF
and increase hepatic artery flow (HAF) post-hepatectomy.
Methods
Study design
The study was undertaken in three parts: an acute pilot study, an acute non-survival series, and a survival pilot
study (Supplementary Figure S1). The acute pilot study provided preliminary data on hemodynamic and biochemical
changes pre/post-hepatectomy+−terlipressin or PCS, and determined the optimal terlipressin-dosing regimen under
terminal anesthesia.
The acute series compared the hemodynamic effects of terlipressin or PCS pre/post-hepatectomy in pigs main-
tained under terminal anesthesia for up to 8 h post-hepatectomy. Pigs were randomized (sealed envelope drawn 1
week prior to surgery), to undergo hepatectomy alone (control); terlipressin followed by hepatectomy or PCS fol-
lowed by hepatectomy. There was no sham group in this series. PVP, PVF, HAF, and mean arterial pressure (MAP)
were recorded continuously. Arterial and portal venous blood and liver biopsies were taken at intervals throughout
the series. Biopsies were also collected post-mortem.
In the survival pilot, pigs underwent 80% hepatectomy alone and were maintained for up to 7 days
post-hepatectomy. There was no comparison group in the survival pilot. PVP and PVF were recorded and cen-
tral/portal venous blood samples were taken daily. Biopsies were collected post-mortem. Data from the survival pilot
are presented in the Supplementary Material.
Animals
All protocols were approved by the Norwegian Animal Research Authority, conducted in compliance with and pre-
sented in accordance with the National Institute of Health’sGuide for the Care and Use of Laboratory Animals [25].
Based on the pilot series, we estimated that to demonstrate a 10% reduction in PVP (i.e. to reduce post-resection PVP
to<10mmHg) with terlipressin or PCS post-hepatectomy, eight animals were required per group. In total 40 castrate
male Norwegian pigs (Sus scrofa domesticus, weight= 32.0+− 5.9 kg) were used: 8 in the acute pilot, 24 in the acute
series, and 8 in the survival pilot.
Anesthesia was administered using an established protocol developed previously within the group [26]. Pigs were
pre-medicated with intramuscular ketamine (20 mg/kg) and atropine (1 mg). Anesthesia was induced with intra-
venous fentanyl (0.01 mg/kg) and isofluorane in oxygen (FiO2 = 0.5, Servo 900, Elema-Scho¨nander/Siemens, Erlan-
gan Germany) and maintained with intravenous fentanyl (0.02 mg/kg/h), midazolam (0.3 mg/kg/h), and isflourane
in oxygen. Ceftriaxone (2 g) was given post-induction.
5-F catheters (CVK, Secalon T, ArgonCritical Care Ltd., Singapore, Singapore) were placed in both internal jugular
veins and left femoral artery (blood sampling andMAP). Intravenous fluids were delivered at 100ml/hwith boluses to
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Figure 1. The effects of terlipressin and direct PCS on PVP, PVF, HAF, and MAP in normal liver (prior to 80% hepatectomy)
Values represent mean +− S.D., n=8 per group. *P<0.05 compared with control (pre-terlipressin or pre-PCS) PVP, PVF, HAF, or MAP.
(A) The effects of terlipressin or PCS on PVP in normal liver. Control compared with terlipressin, P=0.11. Control compared with
PCS, P=0.009. (B) The effects of terlipressin or PCS on PVF in normal liver. Control compared with terlipressin, P=0.003. Control
compared with PCS, P=0.017. (C) The effects of terlipressin or PCS on HAF in normal liver. Control compared with terlipressin,
P=0.001. Control compared with PCS, P=0.012. (D) The effects of terlipressin or PCS on MAP prior to hepatectomy. Control
compared with terlipressin, P<0.0001. Control compared with PCS, P=0.80. Abbreviation: MAP, mean arterial pressure.
maintainMAP> 50mmHg, central venous pressure (CVP) 5–8mmHg, and urine output> 0.5ml/kg/h. If refractory
hypotension developed (MAP<50mmHg for>10min despite volume replacement) norepinephrine (0.025μg/kg/h)
was commenced.
Liver hemodynamic monitoring
Laparotomy was performed through a right-sided, reverse-L incision; 3-mm flow probes were placed around the
left and right hepatic arteries and a 12-mm flow probe around the portal vein (Medistim, Oslo, Norway). A 6-F
double lumen catheter was placed directly into the portal vein (Arrow International, Reading, U.S.A.) and secured
with 5/0 polypropylene sutures. Calibrated transducers (Transpac 3, Abbott Critical Care Systems, Chicago, U.S.A.)
were connected to an amplifier (Gould, 2800S, Ohio, U.S.A.). Pulsatile signals were displayed, digitized, and stored
electronically.
Terlipressin
In the terlipressin group (Glypressin R©, donated by Ferring Pharmaceuticals,West Drayton, U.K.), a 2-mg intravenous
terlipressin bolus was given 20 min pre-hepatectomy and an intravenous terlipressin infusion (0.5–1 mg/h) was com-
menced post-hepatectomy and continued for the duration of the experiment. No placebo was given in the control or
PCS groups.
Direct portacaval shunt
In the shunt group, a side-to-side direct PCS was sutured using continuous 5/0 polypropylene on the infrahepatic
portion of the inferior vena cava, as described previously [6,27] with an increase in shunt diameter from 5 to 8 mm.
Partial (side) clamping of the portal vein and inferior vena cava was required during PCS formation. Shunt patency
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was confirmed by demonstrating PVF reduction following clamp release and by direct inspection and measurement
post-mortem. Hepatectomy was commenced 20 min after completion of PCS.
Eighty percent hepatectomy
Eighty percent hepatectomy was undertaken as previously described [28,29] with minor modifications. The left hep-
atic artery, portal vein, and bile duct were ligated at the hilum. Segments II, III, IV, V, and VIII were resected en bloc
with manual control of the vascular pedicle. The pedicle stump was oversewn with 2/0 polyglactin. Segment VI was
resected by manual control of the vascular VI/VII pedicle and its venous branches oversewn with 2/0 polyglactin, to
leave segments I and VII. Resected wet liver weights were recorded. An estimated remnant liver weight was calculated
using the equation: remnant liver weight (g) = 0.025 × total body weight (g) − resected liver weight (g).
Survival pilot study
In the survival pilot, tunneled single lumen 6-F Broviac catheters (Bard Access Systems Inc, Salt Lake City, U.S.A.)
were placed in each internal jugular vein. The portal catheter and flow probe were tunneled laterally through the
abdominal wall. A feeding gastrostomy (Cook Medical Inc., Bloomington, U.S.A.) was inserted. Lines/cables were
secured with a protective vest (Lomir Biomedical Inc., Malone, U.S.A.). Fluids, analgesia, and antibiotics were given
daily. Blood was taken and CVP, PVP, and PVF were recorded daily under sedation (midazolam 0.15 mg/kg) in the
left-lateral position. HAF/MAP were not recorded and no pigs received/underwent terlipressin/PCS in the survival
series.
Post-mortem
At the end of each experiment, blood, liver, spleen, small bowel, and left kidney biopsies were collected. Probe/catheter
positions were confirmed and the liver+−shunt were weighed/measured.
Biochemistry
Serum aspartate aminotransferase (AST), bilirubin, sodium, potassium, urea, creatinine, and plasma ammonia were
measured using a cobas R© c analyzer (Roche Diagnostics, Indianapolis, U.S.A.); international normalized ratio (INR)
with an STA R© prothrombin time assay kit (Diagnostica Stago SAS, Asnie`res sur Seine Cedex, France); serum lactate
with an ABL 800 flex blood gas analyser (Radiometer Medical ApS, Brønshøj, Denmark); and Lysine-vasopressin
with a (Lys8) vasopressin ELISA kit (Sigma–Aldrich, St. Louis, U.S.A.).
Histological analysis
Liver, small bowel, splenic, and renal biopsies were divided and flash-frozen in liquid nitrogen and stored at−80◦C or
processed for histology, by fixing under vacuum in 10% neutral-buffered formalin for 24 h at 37◦C and stored for up
to 1 month. Histology samples were paraffin-embedded on a ShandonTM ExcelsiorTM ES tissue processor (Thermo
Fisher Scientific Inc., Waltham, U.S.A.). Three millimeter sections were stained with Hematoxylin and Eosin (H &
E).
Hemodynamic analysis
Flow was compared using raw data (ml/min) and flow by liver weight (ml/min/g). The latter was calculated using
the equation: flow/g (ml/min/g) = total flow (ml/min)/0.005 × body weight (g). HAF was the sum of left and right
HAFs. Data are expressed as the mean +− S.D. unless otherwise stated. PVP, PVF, HAF, and MAP were analyzed with
repeated-measures ANOVA, using data extracted from the real-time datamaterial sampled over 10-min intervals and
analyzed using IBMSPSS 22.0 forMacOSX SPSS (IBMCorp., Armonk,NY). Differences were considered statistically
significant at P<0.05.
Results
Pilot data and the effects of terlipressin and direct PCS pre-hepatectomy
Terlipressin and PCS reduced PVP and PVF if given/performed pre- or post-hepatectomy. To standardize the ap-
proach between groups, terlipressin-dosing and PCS were undertaken pre-hepatectomy. The pigs were maintained
for up to 8 h post-hepatectomy, because in the acute pilot experiments there was typically a progressive deterioration
in physiological parameters beyond 8 h.
Following 2 mg terlipressin pre-hepatectomy, PVP remained stable (Figure 1A), PVF decreased (Figure 1B), and
HAF increased (Figure 1C). Following PCS, PVP, and PVF decreased andHAF increased. PCS patencywas confirmed
156 c© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
Clinical Science (2019) 133 153–166
https://doi.org/10.1042/CS20180858
Figure 2. The effects of 80% hepatectomy on PVP, PVF (by liver weight), and HAF were assessed 30 min post-hepatectomy
Values represent mean +− S.D., n=8 per group. *P<0.05 compared with pre-hepatectomy PVP, PVF, PVF by liver weight, or HAF.
(A) The effects of 80% hepatectomy on PVP. Pre compared with post, P<0.0001. (B) The effects of 80% hepatectomy on PVF. Pre
compared with post, P=0.22. (C) The effects of 80% hepatectomy on PVF by liver weight. Pre compared with post, P<0.0001. (D)
The effects of 80% hepatectomy on HAF. Pre compared with post, P=0.002.
by a reduction in PVF from 988+− 296 to 715+− 252 ml/min. The reduction was similar between animals. There were
no differences in PVP, PVF, or HAF between the terlipressin and PCS groups. MAP increased after terlipressin. PCS
had no effect on MAP pre-hepatectomy (Figure 1D).
The segments II, III, IV, V, and VIII resection resulted in a 78.9 +− 2.3% hepatectomy, with an additional cuff of
devascularized parenchyma at the base of segments II/VIII. The average time for hepatectomy was 37 +− 8 min. The
average shunt diameter measured at post-mortem was 8 +− 1 mm.
The effects of hepatectomy on liver and systemic hemodynamics and
biochemistry
In the control group, PVP increased post-hepatectomy and remained elevated throughout the experiment (Figure
2A). There was no change in PVF post-hepatectomy (Figure 2B) although the PVF/g increased (Figure 2C). HAF
decreased post-hepatectomy and remained lower throughout the experiment (Figure 2D).
In the PCS group, four pigs developed refractory hypotension within 3 h of hepatectomy necessitating nore-
pinephrine. One pig in the control group required norepinephrine after 3 h. Norepinephrine was not required in
the terlipressin group. CVP was maintained between 5 and 8 mmHg and urine output> 0.5 ml/kg/h throughout the
experiment. Urine output increased in the terlipressin group compared with control and PCS groups.
Figure 3A–D summarizes the biochemistry from the acute series. Sodium, potassium, urea, and creatinine (not
shown) remained within normal limits in all groups throughout the series. Bilirubin (Figure 3A), lactate (Figure 3B),
INR, and AST increased in all groups but no differences were detected between groups. Ammonia increased in all
groups and was greater in the PCS group at 3 h compared with control (Figure 3C). Lys-vasopressin was detected in
all groups. Levels remained at baseline in the control and PCS groups and increased in the terlipressin group (Figure
3D).
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Figure 3. Serum bilirubin, serum lactate, plasma ammonia, and serum lys-vasopressin at 3 h post hepatectomy
Values represent mean +− S.D., n=8 per group. *P<0.05 compared with control (hepatectomy alone) bilirubin, lactate, ammonia,
or terlipressin. (A) Bilirubin at 3 h post-hepatectomy. Control compared with terlipressin, P=0.18. Control compared with PCS,
P=0.31. (B) Lactate at 3 h post-hepatectomy. Control compared with terlipressin, P=0.37. Control compared with PCS, P=0.09.
(C) Ammonia at 3 h post-hepatectomy. Control compared with terlipressin, P=0.11. Control compared with PCS, P=0.03. (D)
Lys-vasopressin at 3 h post-hepatectomy. Control compared with terlipressin, P<0.0001. Control compared with PCS, P=0.50.
In the survival pilot 80% hepatectomy was undertaken with 100% at 1-day and 62% at 3-day survival. The pigs
experienced significant morbidity (pain and ascites) post-hepatectomy. PVP increased and remained elevated up
to day 5 post-hepatectomy (Supplementary Figure S2A). PVF initially decreased post-hepatectomy, then by 12 h
PVF had increased from baseline and remained elevated up to day 5 (Supplementary Figure S2B). HAF was not
measured in the survival experiments. Serum sodium, potassium, and urea were within normal limits throughout the
survival pilot. Serumcreatinine increased onday 1, and returned to baseline by day 2. Serumbilirubin (Supplementary
Figure S2C) peaked on day 2. INR (Supplementary Figure S2D), AST (Supplementary Figure S2E), and ammonia
(Supplementary Figure S2F) peaked on day 1. INR normalized by day 4. Bilirubin, AST, and ammonia remained
elevated throughout the survival pilot.
The effects of terlipressin and PCS on PVP post-hepatectomy
Figure 4A traces the continuousmedian PVP for representative measurements for all pigs in each group over 10-min
intervals: baseline; pre-hepatectomy but post-terlipressin/PCS; and post-hepatectomy. There were no differences in
baseline PVPbetween groups. PVP increased post-hepatectomy frombaseline and remained elevated for the duration
of the study. There was no difference in baseline and post-hepatectomy PVP in the terlipressin and PCS groups for
the duration of the study.
Figure 4B–E summarizes themeanPVPof representative 10-min intervals sampled immediately post-hepatectomy
and hourly throughout the acute series. Terlipressin reduced post-hepatectomy PVP within 1 h and its effects were
sustained throughout the series when compared with the control group and not within the terlipressin group. PCS
reduced post-hepatectomyPVP for up to 4 h post-hepatectomywhen comparedwith the control group andnotwithin
the PCS group. There was no difference in PVP between the terlipressin and PCS groups throughout the series.
The effects of terlipressin and PCS on PVF post-hepatectomy
Figure 5A traces the continuous median PVF for representative measurements for all pigs in each group over 10-min
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Figure 4. The effects of terlipressin and PCS on PVP following 80% hepatectomy
(A) Values represent continuous median PVP for all pigs in each group sampled over representative 10-min intervals and processed
using scale space analysis: pre-hepatectomy (left), post-terlipressin, or PCS but before hepatectomy (middle) and 1 h post-hepa-
tectomy (right). Hepatectomy alone (black), terlipressin + hepatectomy (blue) and PCS + hepatectomy (pink). The x-axis represents
time in minutes, Values in (B–E) represent mean +− S.D. of representative 10-min intervals of PVP sampled out to 6 h post hepa-
tectomy, n=8 per group. *P<0.05 compared with control: (B) immediately post-hepatectomy (T0); (C) 1–2 h; (D) 3–4 h; (E) 5–6 h
(Supplementary Table S1). Values represent median PVP of three 10-min intervals sampled for all pigs in each group processed
using scale space analysis.
intervals. There were no differences in pre/post-hepatectomy PVF in the control, terlipressin (P=0.84), or PCS
(P=0.21) groups. PVF/g increased in all groups post-hepatectomy (not shown).
Figure 5B–E summarizes the mean PVF for representative intervals sampled over the post-hepatectomy period.
Terlipressin and PCS led to reductions in PVF throughout the series post-hepatectomy when compared with the
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Figure 5. The effects of terlipressin and PCS on PVF following 80% hepatectomy
(A) Values represent continuous median PVF for all pigs in each group sampled over representative 10-min intervals and processed
using scale space analysis: pre-hepatectomy (left), post-terlipressin, or PCS but before hepatectomy (middle) and 1 h post-hepa-
tectomy (right). Hepatectomy alone (black), terlipressin + hepatectomy (blue) and PCS + hepatectomy (pink). The x-axis represents
time in minutes. Values in (B–E) represent mean +− S.D. of representative 10-min intervals of PVF sampled out to 6 h post-hepa-
tectomy, n=8 per group. *P<0.05 compared with control: (B) immediately post-hepatectomy (T0); (C) 1–2 h; (D) 3–4 h; (E) 5–6 h
(Supplementary Table S2).
control group and not within the terlipressin nor the PCS groups. There were no differences in PVF between the
terlipressin and PCS groups throughout the series.
The effects of terlipressin and PCS on HAF post-hepatectomy
Figure 6A traces the continuous median HAF for all pigs in each group over 10-min intervals. HAF decreased in the
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Figure 6. The effects of terlipressin and PCS on HAF following 80% hepatectomy
(A) Values represent continuous median PVP for all pigs in each group sampled over representative 10-min intervals and processed
using scale space analysis: pre-hepatectomy (left), post-terlipressin, or PCS but before hepatectomy (middle) and 1 h post-hepate-
ctomy (right). Hepatectomy alone (black), terlipressin+hepatectomy (blue) and PCS+hepatectomy (pink). The x-axis represents time
in minutes. Values in (B–E) represent mean +− S.D. of representative 10-min intervals of HAF sampled out to 6 h post-hepatectomy,
n=8 per group. *P<0.05 compared with control and **P<0.05 compared with PCS: (B) immediately post-hepatectomy (T0); (C) 1–2
h; (D) 3–4 h; (E) 5-6 h (Supplementary Table S3).
hepatectomy alone, terlipressin (P=0.003) and PCS (P=0.024) groups post-hepatectomy.
Figure 6B–E summarizes the mean HAF for representative intervals sampled over the post-hepatectomy period.
Immediately post-hepatectomy HAF in the terlipressin group exceeded HAF in the PCS group but not the control.
After 1 h HAF in the terlipressin group was greater than control and remained higher for up to 7 h post-hepatectomy.
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HAF in the terlipressin group also exceeded that of the PCS group for prolonged intervals post-hepatectomy. There
was no difference in HAF between the PCS and control groups throughout the series.
Histology
There were variations in the baseline liver tissue within and between groups, in terms of steatosis, hepatocyte staining,
sinusoidal diameter, and presence of intra-sinusoidal mononuclear cells. All groups demonstrated extravasation of
red cells 2 h post-hepatectomy with progressive portal edema (Supplementary Figure S3A) and neutrophil migration
appearing 6 h post-hepatectomy. The extent of red cell extravasation andportal edema in the pigs receiving terlipressin
was reduced at later time points compared with the control pigs. No proliferative markers were assessed in this acute
study. It was not possible to quantitate these differences using image analysis. No evidence of splenic, kidney, or small
bowel pathology was detected across the acute series.
In the survival pilot, up to 3 days post-hepatectomypost-mortem liver histology demonstrated variable venous con-
gestion, sinusoidal dilatation, and sinusoidal mononuclear cell infiltration. No biliary changes were demonstrated up
to day 3. There was evidence of hepatocyte and non-parenchymal cell regeneration. From days 4–7 sinusoidal dilata-
tion and venous congestion persisted. In addition, there was evidence of inflammation, biliary injury [desquamation
and infarction (Supplementary Figure S3B)] and steatosis (Supplementary Figure S3C). Regenerative changes were
less evident than in earlier post-mortem specimens. All splenic biopsies from the survival pilot demonstrated venous
congestion. Small bowel biopsies demonstrated bowel wall thickening. There was no evidence of kidney pathology.
Discussion
The present study demonstrates that 80% hepatectomy in the pig increases PVP and PVF/g and reducesHAF, and that
terlipressin and PCS attenuate these effects in a terminal anesthetic model. Although previous studies have demon-
strated the effects of PCS on liver hemodynamics post-hepatectomy in pigs [6,7] and of terlipressin post-hepatectomy
in rodents [22–24], this is the first study to report the effects of terlipressin on liver hemodynamics post-hepatectomy
in a non-cirrhotic porcine model.
The effects of terlipressin and PCS were characterized using a terminal anesthetic model, previously developed
within our group [30–32]. This enabled multiple, continuous pressure and flow measurements to be recorded simul-
taneously while minimizing morbidity in the study group. While it is feasible to measure liver and systemic hemo-
dynamics at intervals post-hepatectomy in a survival setting [7,29], in our experience there is greater variability in
PVP and PVF between pigs (due to the physiological instability that accompanies the ensuing PLF) and the animals
are exposed to significant morbidity. The terminal anesthetic model allowed us to demonstrate continuous real-time
physiology in the early phase post-hepatectomy. The limitation of thismodel is that it does not enable characterization
of liver hemodynamics beyond 8 h.
In the survival pilot, after 80% hepatectomy PVP and PVF changes were sustained for 5 days and accompanied
by significant liver dysfunction. This clinical course was comparable with existing studies [29]. Histology 1-week
post-hepatectomy demonstrated hepatic sinusoidal dilatation, venous congestion, steatosis, and inflammation within
a regenerating liver. There are limited reports of histological changes in pig liver after extended hepatectomy. Similar
patterns may be observed in patients who develop small-for-size syndrome after split-liver transplantation, where
liver biopsies taken within the first 10 days post-transplantation demonstrate venous congestion, sinusoidal injury,
steatosis, and cholestasis [33]. With the exception of cholestasis (often a later change), these features were present in
the survival pilot.
Previous studies have demonstrated that 80% hepatectomy in the pig increases PVP, leads to liver dysfunction and
increases mortality [29]. In this terminal anesthetic study, 80% hepatectomy led to a PVP increase. Both terlipressin
and PCS maintained PVP at pre-resection levels after 80% hepatectomy for the duration of the study. In addition,
post-hepatectomy PVP was significantly lower than in the control group for up to 4 h in the PCS group and up to 6
h in the terlipressin group. If this effect was sustained in a survival model, terlipressin and PCS could have an impact
on rates of liver dysfunction.
The post-hepatectomy PVP increase in pigs is less than the PVP increase following equivalent resections in pa-
tients [4], although their clinical course is comparable [29]. The difference in post-hepatectomy PVP between pig
and human liver may be explained by variations in parenchymal compliance, venous outflow, and the presence of un-
reported parenchymal disease in patients undergoing major hepatectomy. The cause for variation in baseline tissue
is unknown, but was not thought to have impacted on differences in liver hemodynamics between groups, as the pigs
were randomized pre-operatively and there was no fibrosis or cirrhosis detected in the baseline liver biopsies.
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The hepatic artery buffer response autoregulates liver blood flow. When PVF increases, HAF decreases and vice
versa [34,35]. This was demonstrated pre-hepatectomy in normal liver where both terlipressin and PCS reduced PVF
resulting in an increase in HAF [7].
Post-hepatectomy terlipressin reduced PVF and increased HAF compared with the control group. Vasopressin
exerts a biphasic response on HAF. If infused directly into the hepatic artery vasopressin leads to hepatic artery vaso-
constriction. When it is given systemically, vasopressin causes splanchnic vasoconstriction; reducing PVF, which
in turn increases HAF, through the buffer response [36]. PCS reduced PVF and increased HAF pre-hepatectomy.
Post-hepatectomy showed no difference in HAF as demonstrated when compared with control. Interpretation of the
hemodynamic effects of PCS on HAF is difficult because 50% of pigs in the PCS group required norepinephrine,
which is likely to have had a direct vasoconstrictive effects on the hepatic artery [37].
The decreased oxygen delivery that results from HAF reduction, together with the venous congestion that arises
from increasing PVF/g, may induce hypoxia in the remnant liver, precipitating a cycle of inflammation and impaired
regeneration, which could exacerbate liver dysfunction. This process may have parallels with ischemia–eperfusion
injury [38].
Eighty percent hepatectomy+PCS caused hemodynamic instability that required supplementary fluids and nore-
pinephrine 3–4 h post-hepatectomy. No pigs receiving terlipressin required norepinephrine. MAP increased signif-
icantly following administration of terlipressin. It is likely that terlipressin-induced arteriolar vasoconstriction aug-
mented MAP, however the absence of information regarding cardiac index or vascular resistance, limits the ability to
distinguish true terlipressin-induced changes.
Direct PCS was used as this had previously been demonstrated to modulate liver dysfunction in pigs after major
hepatectomy [6]. The increased hemodynamic instability in the PCS group was an unexpected finding. While the
duration of partial portal clamping was minimized during shunt formation, portal clamping is very poorly tolerated
in pigs and this may have contributed to instability following PCS. Future studies may compare the use of mesocaval
shunting or use of an interposition graft to minimize the impact of portal clamping in this porcine model.
The aim of the terlipressin-dosing regimen was to maintain stable PVP reduction. As lys-vasopressin is metabo-
lized rapidly by the pig, terlipressin infusion was required to achieve stable PVP reduction. This contrasts with the
terlipressin activity in humans, where clearance is slower and hence bolus terlipressin-dosing achieves stable PVP
reduction. No direct side effects of terlipressin (renal dysfunction, hyponatremia, or cardiovascular effects) were ob-
served, but these should be explored in a survival model.
Lactate and ammonia provided the most direct markers of liver dysfunction. The increased plasma ammonia ob-
served in the PCS group supports concerns about exacerbating encephalopathy when modulating portal inflow at
the time of liver surgery. There were no quantitable differences in liver histology between groups. In survival series,
peak liver dysfunction does not occur until beyond day 1 post hepatectomy [29], as was demonstrated in our survival
pilot. The biochemical profile immediately after 80% hepatectomy has not been described previously.
Currently there is no established therapy to prevent/treat PLF in non-cirrhotic patients. PCS [6,7], splenic artery
ligation [39,40], splenectomy [41,42], and portal banding [9] have all been used to modulate post-hepatectomy
PVP and prevent PLF. The degree and duration of PVP reduction required to prevent PLF in non-cirrhotic liver
post-hepatectomy is unknown [4]. While surgical approaches may achieve more pronounced/sustained PVP reduc-
tion, the additional surgical morbidity associated may not be justified. Reduction in post-resection PVP with ter-
lipressin in non-cirrhotic patients could offer several advantages over surgical strategies because terlipressin does
not require additional interventions (to close the shunt or remove the portal band) and may avoid morbidity associ-
ated with surgical PVP modulation (encephalopathy and circulatory dysfunction). These benefits must be balanced
against potential adverse effects that can occur at higher terlipressin doses. A stepwise approach to post-resection
PVP modulation could be employed. For example, elevated PVP could initially be treated with terlipressin then if
PVP is refractory or terlipressin is tolerated poorly, a surgical technique could be considered.
While previous studies have evaluated the dose, toxicity, and pharmacodynamics of terlipressin in cirrhotic pa-
tients [14–20], equivalent data in non-cirrhotic patients are limited. It is not possible to translate data from cir-
rhotic to non-cirrhotic patients directly because there are major differences in hepatic and systemic hemodynam-
ics [43]. A phase I study is required to confirm the safe dose and initial proof-of-concept in non-cirrhotic patients
post-hepatectomy.
There are limitations to the present study. The impact of terlipressin and PCS were evaluated in a terminal anes-
thetic study. It was, therefore, not possible to determine the effects of terlipressin or PCS on PLF or survival. The
late hemodynamic instability that developed in the PCS group limits the ability to compare PCS with terlipressin.
The mechanism for this instability is uncertain but may reflect the impact of partial portal clamping duration shunt
formation.
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The anesthetic agents are likely to have caused fluctuations in liver hemodynamics. However, the anesthetic proto-
col was developed to minimize hemodynamic changes within the liver and was standardized between groups. Future
studies examining the impact of terlipressin/PCS on PLF should be undertaken in a survival series. The present pa-
per has not presented detailed characterization of the pathogenesis of liver injury. Subsequent studies should examine
differences in immunohistochemistry and gene expression between groups.
In conclusion, the PVP and PVF reduction induced by terlipressin and PCS post-hepatectomy, suggests these in-
terventions may have a role in in the prevention/treatment of PLF. Further evaluation should be undertaken in the
setting of a survival series and multicenter controlled trial.
Clinical perspectives
• PVP can increase greatly after major liver resection, thereby increasing the risk of developing PLF,
which may be prevented by maintaining PVP in the normal range.
• In this large animal study we demonstrate, for the first time, that terlipressin can prevent the increase
in PVP after major liver resection in a large animal model. The effect of terlipressin was similar to that
of portacaval shunting.
• The role of terlipressin in preventing PLF in humans merits investigation.
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